Exelixis
NasdaqGS:EXEL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 55 Fair Values set on narratives written by author
WA
Consensus Narrative from 23 Analysts
Zanza Development And Oncology Alliances Will Drive Future Success
Key Takeaways Strategic alliances and expansion into oncology sectors aim to enhance revenue growth through cost-sharing and pivotal trials. A disciplined R&D focus on late-stage assets and share buybacks supports financial strength and EPS growth.
View narrativeUS$35.74
FV
3.1% overvalued intrinsic discount9.27%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
24 days ago author updated this narrative